

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL, REQUIRE REGISTRATION OR ANY OTHER MEASURES. SEE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.

## The subscription period in Active Biotech's rights issue begins today

Today, on November 25, 2025, is the first day of the subscription period in Active Biotech AB's (publ) ("Active Biotech" or the "Company") (Nasdaq Stockholm) rights issue of shares of approximately SEK 70.3 million, that was resolved by the Board of Directors on October 17, 2025, and approved by the extraordinary general meeting on November 19, 2025 (the "Rights Issue"). Through an over-allotment option the Company can receive an additional maximum of SEK 10.0 million (the "Over-Allotment"). The subscription period runs until December 9, 2025. However, please note that some banks and nominees may have an earlier response deadline for subscription in the Rights Issue. Shareholders should therefore check with their bank or nominee if they have an earlier response date for the subscription.

### Information Document

- The net proceeds from the Rights Issue will fund the advancement of the on-going proof-of-concept studies with tasquinimod in myelofibrosis to expected finalization in the end of 2027, business development activities of laquinimod to secure its continued development in inflammatory eye diseases, and general corporate purposes to the end of 2027.
- The Rights Issue comprises up to 1,405,902,488 shares with a subscription price of SEK 0.05 per share. If the Rights Issue is fully subscribed, the Company will receive approximately SEK 70.3 million before deduction of costs related to the Rights Issue.
- Through the Over-Allotment option the Company can receive an additional maximum of SEK 10.0 million by issuance of an additional maximum 200,000,000 shares at the same price as in the Rights Issue.
- Each share in the Company held on the record date November 21, 2025 entitles the holder to one (1) subscription right. Seven (7) subscription rights entitle the holder to subscribe for eight (8) new shares.
- The last day of trading in the Company's shares including the right to participate in the Rights Issue was November 19, 2025.
- The subscription period for the Rights Issue will run from today through December 9, 2025.
- Trading in subscription rights will take place on Nasdaq Stockholm during the period from today through December 4, 2025, and trading in paid subscribed shares ("BTA") will occur during the period from today through December 23, 2025.

- The Rights Issue is covered by subscription commitments and underwriting commitments corresponding to 100 percent of the issue amount. However, the subscription commitments and the underwriting commitments are not secured by bank guarantees, escrow accounts, pledges or similar arrangements.
- The board's resolution on the Rights Issue was approved by an extraordinary general meeting on November 19, 2025.
- No prospectus will be prepared in connection with the Rights Issue. The Company has prepared and published an information document (the “**Information Document**”) in accordance with Article 1.4 db of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (the “**Prospectus Regulation**”).
- Complete terms and conditions and instructions for the Rights Issue, as well as other information, are set out in the Information Document which has been registered with the Swedish Financial Supervisory Authority (Finansinspektionen) and is available on the Company's website [www.activebiotech.com](http://www.activebiotech.com).

### Timetable for the Rights Issue

25 November – 9 December 2025	Subscription period.
25 November – 4 December 2025	Trading in subscription rights.
25 November – 23 December 2025	Trading in paid subscribed shares (BTA).
10 December 2025	Planned date for disclosure of the final outcome of the Rights Issue.
5 January 2026	Trading in new shares.*
*Note that depending on different routines at different banks and custodians the trading may begin before or after this date.	

### Advisors

Active Biotech has engaged DNB Carnegie Investment Bank and Advokatfirman Vinge as financial and legal advisors, respectively, in connection with the Rights Issue.

### For more information, please contact:

Helén Tuveßon, CEO

Tel: +46 46 19 21 56

E-mail: [helen.tuveßon@activebiotech.com](mailto:helen.tuveßon@activebiotech.com)

Hans Kolam, CFO

Tel: +46 46 19 20 44

Email: [hans.kolam@activebiotech.com](mailto:hans.kolam@activebiotech.com)

### About Active Biotech

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that develops first-in-class immunomodulatory treatments for oncology and immunology indications with a high unmet medical need and significant commercial potential. Active Biotech currently holds three projects in its portfolio, of which tasquinimod and laquinimod are wholly owned small molecule immunomodulators with a mode of action that includes modulation of myeloid immune cell function. The projects are in clinical development for hematological malignancies and inflammatory eye disorders, respectively. The company's core focus is on the development of tasquinimod in

myelofibrosis, a rare blood cancer, where clinical proof-of-concept studies have been initiated. A clinical Phase Ib/IIa study in multiple myeloma has been concluded. Laquinimod is in clinical development for the treatment of non-infectious uveitis. A clinical phase I program with a topical ophthalmic formulation has been performed to support phase II development together with a partner. The third pipeline project is naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, which is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit [www.activebiotech.com](http://www.activebiotech.com) for more information.

### Important information

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to legal restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Active Biotech in any jurisdiction, neither from Active Biotech nor from someone else.

This press release is not a prospectus for the purposes of the Prospectus Regulation and has not been approved by any regulatory authority in any jurisdiction. No prospectus will be prepared in connection with the Rights Issue. The Company has prepared and published an Information Document in the form provided for in Annex IX of the Prospectus Regulation.

This press release does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Company. The information contained in this announcement relating to the Rights Issue is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this press release or its accuracy or completeness.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “**Securities Act**”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public Rights Issue of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the United States, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “**Order**”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as

"relevant persons"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

#### *Forward-looking statements*

This press release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's and the group's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company and the group operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is required by law or Nasdaq Stockholm's rule book for issuers.

The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

As Active Biotech is deemed to carry out activities worthy of protection in accordance with the Swedish Screening of Foreign Direct Investments Act (Sw. *lag (2023:560) om granskning av utländska direktinvesteringar*), certain investments in the Rights Issue may require examination by the Inspectorate for Strategic Products.

#### **Attachments**

---

**The subscription period in Active Biotech's rights issue begins today**